Integrated Filing- Financial

Gland Pharma has announced a board meeting to review its financial results for the quarter and nine months ended December 31, 2024. The company reported a total revenue from operations of ₹13,840.52 million and utilized expenses amounting to ₹11,432.44 million, leading to a profit before tax of ₹2,993.02 million.

The net profit for the period stands at ₹2,046.92 million.

This earnings report underscores a sound performance, despite losses from its subsidiaries, which may cause some investor caution.

Overall, this update could be viewed positively due to the company's operational stability and revenue generation potential.